time
work
oncolyt
virus
take
stock
statu
field
dispos
array
potenti
therapeut
agent
begin
conduct
earlyphas
clinic
trial
patient
relapsedmetastat
cancer
draw
lesson
learn
develop
biolog
therapi
monoclon
antibodi
target
small
molecul
inhibitor
posit
chart
cours
next
wave
trial
go
beyond
phase
studi
safeti
feasibl
articl
review
approach
develop
oncolyt
virus
cancer
therapeut
emphasis
fact
process
modular
involv
multipl
iter
step
laboratori
clinic
ultim
least
medium
term
futur
oncolyt
virotherapi
lie
combin
regimen
standard
anticanc
agent
radiat
chemotherapi
clinic
develop
oncolyt
virus
infanc
mani
obstacl
overcom
agent
prove
truli
make
contribut
manag
cancer
patient
present
field
suffer
seriou
credibl
problem
critic
acknowledg
conceptu
beauti
use
fine
craft
selfrepl
molecular
machin
seek
destroy
locoregion
system
deposit
cancer
point
fact
host
immun
respons
inevit
prove
insuper
barrier
effect
system
therapi
addit
mani
observ
oncolyt
virotherapi
tar
brush
gene
therapi
disciplin
seen
offer
much
deliv
littl
consid
current
state
oncolyt
virotherapi
mean
counterbalanc
pessim
exist
use
rememb
lesson
learn
develop
biolog
therapi
mani
new
agent
held
exemplar
power
biomed
scienc
deliv
therapeut
benefit
circuit
often
rocki
road
clinic
approv
first
set
lesson
come
clinic
develop
monoclon
antibodi
follow
initi
descript
huge
enthusiasm
potenti
specif
select
anticanc
drug
base
abil
target
uniqu
tumourassoci
antigen
howev
first
wave
expect
yield
emerg
despond
becam
clear
system
administ
antibodi
fail
reach
target
tumour
tissu
high
concentr
reason
familiar
virotherapist
attrit
nonspecif
specif
adsorpt
nontarget
tissu
immunemedi
clearanc
foreign
antigen
earli
monoclon
antibodi
frequent
murin
origin
account
vast
major
inject
antibodi
dose
human
antimous
antibodi
hama
respons
alter
pharmacokinet
subsequ
antibodi
infus
also
expos
patient
risk
immunemedi
advers
event
quarter
sens
antibodi
would
fail
make
mark
clinic
arena
howev
scientist
clinician
wrestl
problem
emerg
two
clear
strand
thought
immun
respons
monoclon
antibodi
seen
potenti
therapeut
right
ii
effort
made
reduc
immunogen
antibodi
molecul
make
less
visibl
immun
system
consider
familiar
work
field
virotherapi
direct
parallel
current
debat
role
immun
respons
oncolyt
virotherapi
one
hand
persuas
data
show
intact
immun
system
requir
oncolyt
virotherapi
order
mediat
optim
antitumour
efficaci
espous
view
oncolyt
virotherapi
essenti
form
immunotherapi
review
hand
studi
suggest
judici
suppress
immun
respons
significantli
improv
system
deliveri
oncolyt
virotherapi
result
enhanc
intratumour
viral
replic
treatment
efficaci
review
step
taken
make
monoclon
antibodi
clinic
success
clear
greatest
benefit
result
reduc
immunogen
rather
attempt
exploit
abil
rais
antiantibodi
immun
respons
studi
perform
attempt
made
blunt
hama
respons
administ
antit
cell
immunosuppress
drug
rel
littl
success
gener
chimer
murinehuman
fulli
humanis
monoclon
antibodi
agent
abl
enter
clinic
larg
number
inde
number
monoclon
antibodi
licens
routin
clinic
use
malign
diseas
clearli
correspond
human
viral
protein
go
possibl
number
way
antigen
epitop
may
mask
immun
system
either
load
virus
onto
human
carrier
cell
cloak
surfac
polym
second
set
lesson
learn
develop
biolog
therapi
come
new
gener
small
molecul
gener
inhibitor
key
signal
transduct
pathway
cancer
cell
last
year
number
agent
demonstr
efficaci
randomis
phase
ii
iii
trial
receiv
approv
regulatori
agenc
howev
except
rare
diseas
reliant
defect
singl
signal
pathway
eg
gastrointestin
stromal
tumour
ckit
mani
agent
show
modest
singleag
activ
establish
treatmentresist
cancer
furthermor
even
show
dramat
singleag
efficaci
inevit
follow
emerg
treatment
resist
result
adapt
genet
alter
tumour
result
consider
wide
accept
futur
develop
target
therapi
occur
part
combin
therapeut
regimen
use
alongsid
standard
anticanc
therapi
radiotherapi
chemotherapi
therefor
translat
cliniciansscientist
work
oncolyt
virotherapi
direct
studi
abundantli
clear
studi
focu
understand
integr
oncolyt
virus
standard
agent
order
achiev
therapeut
synergi
minimis
normal
tissu
toxic
review
describ
initi
attempt
build
integr
programm
iter
preclin
clinic
research
allow
us
evalu
use
oncolyt
virus
cytotox
chemotherapi
radiotherapi
process
use
oncolyt
reoviru
reason
believ
approach
adopt
rang
oncolyt
agent
ultim
aim
programm
move
oncolyt
virotherapi
therapeut
agenda
use
earlier
patient
treatment
hisher
diseas
becom
multipli
resist
goal
firm
foundat
lesson
learn
develop
biolog
therapi
last
year
cetuximab
shown
enhanc
therapeut
efficaci
radic
radiotherapi
randomis
phase
iii
trial
median
overal
surviv
increas
month
result
achiev
despit
fact
antiegfrtarget
therapi
rel
poor
singleag
respons
rate
reoviru
respiratori
enter
orphan
viru
member
reovirida
famili
reoviru
ubiquit
isol
untreat
sewag
stagnant
water
river
throughout
world
name
suggest
reoviru
infect
respiratori
gastrointestin
tract
associ
name
human
diseas
although
infrequ
caus
flulik
upper
respiratori
tract
symptom
mild
diarrhoeal
ill
exposur
reoviru
common
healthi
human
adult
show
seroposit
virion
consist
nonenvelop
icosahedr
capsid
doubl
shell
protein
genom
compris
doublestrand
rna
split
segment
three
size
design
l
depend
size
segment
genom
structur
thwart
attempt
gener
genet
engin
reovirus
progress
recent
made
area
oncolyt
natur
reoviru
first
recognis
wildtyp
reoviru
shown
replic
transform
normal
cell
cell
express
high
level
egfr
verbb
truncat
mutant
egfr
shown
suscept
reoviru
infect
cytotox
detail
analysi
demonstr
activ
ra
pathway
signal
pathway
downstream
egfr
prerequisit
sensit
reoviru
ra
pathway
frequent
activ
cancer
either
mutat
ra
gene
overexpressionmut
activ
egfr
reovir
infect
normal
cell
lead
activ
protein
kinas
r
pkr
serin
threonin
protein
kinas
requir
bind
doublestrand
rna
phosphoryl
becom
activ
fig
pkr
main
function
act
defenc
viral
infect
contribut
antiprolif
respons
interferon
follow
viral
infect
howev
cell
harbour
activ
ra
mutat
pkr
remain
hypophosphoryl
inact
state
allow
reovir
protein
synthesi
continu
freeli
result
viral
replic
proce
cell
lysi
occur
cell
line
origin
almost
common
tumour
type
found
suscept
reovir
oncolysi
intratumour
intraven
inject
reoviru
shown
caus
regress
varieti
syngen
xenograft
tumour
immunocompet
immunodefici
anim
model
respect
review
contrast
phase
trial
small
molecul
monoclon
antibodi
studi
involv
oncolyt
virus
face
number
addit
organis
legal
ethic
issu
consider
extrem
import
given
fact
public
percept
virus
base
experi
caus
diseas
recent
press
coverag
viral
diseas
sever
acut
respiratori
syndrom
coronaviru
sar
swine
flu
pandem
ad
gener
cautiou
view
virus
potenti
therapeut
despit
fact
us
enrol
patient
clinic
trial
attest
real
willing
among
patient
hear
potenti
use
ancient
foe
therapeut
benefit
inde
author
collect
person
experi
patient
discourag
take
part
studi
mere
propos
studi
agent
viru
anyth
attend
safeti
measur
come
part
trial
design
often
view
patient
oner
allow
contempl
trial
particip
perhap
surpris
greatest
degre
caution
area
come
regulatori
author
overse
clinic
trial
oncolyt
virotherapi
organis
includ
nation
region
local
bodi
place
appropri
strong
emphasi
safeti
consider
direct
risk
patient
staff
public
larg
result
clinic
studi
tend
conduct
condit
stringent
biosafeti
detail
analysi
risk
vector
shed
environment
contamin
studi
agent
unfortun
local
level
signific
variabl
oper
characterist
safeti
committe
set
supervis
trial
involv
genet
modifi
organ
local
variat
rule
practic
fact
repres
singl
greatest
obstacl
studi
initi
enrol
complet
embark
programm
research
novel
biolog
agent
import
appreci
necessari
conduct
work
modular
project
regular
iter
step
bench
bedsid
fig
inde
work
epitom
true
translat
work
allow
lesson
learn
laboratori
shape
clinic
trial
design
directli
analysi
clinic
materi
laboratori
inform
ongo
preclin
experi
studi
natur
design
provid
initi
platform
subsequ
work
programm
built
repres
huge
hurdl
small
biotechnolog
compani
clear
requir
signific
financi
invest
often
modest
chanc
achiev
suffici
eyecatch
result
guarante
progress
phase
ii
evalu
earli
exampl
trial
concern
perceiv
risk
administ
live
virus
cancer
patient
led
regul
insist
extraordinarili
cautiou
doseescal
scheme
trial
took
long
time
reach
dose
level
biolog
effect
might
anticip
thank
literatur
contain
suffici
bodi
reassur
data
number
phase
studi
oncolyt
virotherapi
assuag
concern
regul
nonetheless
like
new
viral
agent
especi
firstinfamili
still
go
rel
labori
earli
stage
clinic
develop
consid
clinic
develop
reoviru
templat
whole
develop
process
firstinman
experi
came
intratumour
administr
first
studi
patient
varieti
malign
receiv
escal
dose
intratumour
reoviru
level
rang
singl
inject
plaqu
form
unit
pfu
three
inject
pfu
main
symptom
headach
flulik
ill
grade
event
report
best
respons
follow
complet
respons
patient
partial
respons
patient
stabl
diseas
patient
subsequ
studi
focus
patient
glioma
patient
recurr
diseas
dose
dose
level
n
n
n
tissu
cultur
infecti
tcid
intratumour
inject
treatment
well
toler
grade
toxic
encount
median
time
progress
week
patient
show
diseas
stabil
data
intratumour
inject
unpublish
data
prostat
cancer
patient
form
basi
submiss
conduct
firstinman
studi
intraven
reoviru
patient
advanc
cancer
thirtythre
patient
receiv
escal
dose
reoviru
day
tcid
day
repeat
total
cycl
reoviru
deliv
median
number
maximum
number
cycl
administ
doselimit
toxic
escal
limit
limit
impos
viral
manufactur
previou
phase
intratumour
studi
domin
toxic
mild
consist
viru
infect
consist
fever
fatigu
headach
interestingli
effect
appear
independ
viru
dose
treatment
cycl
view
concern
viral
excret
environment
contamin
studi
includ
detail
analysi
blood
urin
fecal
urinari
sampl
revers
transcript
pcr
analys
confirm
neg
preand
posttreat
blood
urin
saliva
fecal
sampl
reoviru
use
rtpcr
screen
base
cycl
amplif
use
decisionmak
regard
patient
suitabl
discharg
hospit
subsequ
reanalysi
data
base
cycl
amplif
detect
limit
tcid
reveal
weak
posit
signal
first
cycl
reoviru
treatment
small
number
patient
day
patient
abl
obtain
preand
posttreat
biopsi
sampl
demonstr
recoveri
replicationcompet
viru
data
import
confirm
abil
viru
reach
tumour
system
administr
data
tumour
deliveri
viru
even
impress
view
light
result
analys
antivir
immun
respons
signific
increas
neutralis
antireovir
antibodi
nara
seen
peak
endpoint
titr
reach
one
patient
overal
median
increas
nara
titr
rang
also
conduct
analysi
dynam
chang
cellmedi
immun
paramet
nk
cell
cell
gener
show
immunostimulatori
effect
albeit
signific
patienttopati
variabl
taken
togeth
data
indic
fact
even
heavili
pretreat
patient
capabl
mount
dynam
immun
respons
treatment
system
virotherapi
demonstr
signific
humor
antivir
immun
respons
follow
intraven
administr
reoviru
phase
studi
subsequ
preclin
studi
perform
part
iter
process
improv
system
oncolyt
virotherapi
examin
intraven
deliveri
multipl
dose
reoviru
immunocompet
mice
bear
subcutan
tumour
show
low
level
viru
abl
reach
tumour
furthermor
therapeut
experi
activ
intraven
reoviru
modest
best
lung
metastas
subcutan
tumour
light
previou
studi
report
improv
activ
combin
immunosuppress
agent
cyclophosphamid
oncolyt
virotherapi
test
approach
model
combin
intraven
reoviru
highdos
cyclophosphamid
mgkg
day
mani
barrier
effect
intratumour
deliveri
replic
overcom
biodistribut
studi
viral
titer
pfu
per
mg
recov
tumour
therapeut
studi
associ
mark
tumour
regress
first
week
therapi
follow
death
anim
unfortun
surprisingli
found
titer
viru
could
also
recov
circul
number
normal
tissu
notabl
heart
level
recoveri
reoviru
cardiac
tissu
consist
reovir
replic
within
cardiac
myocyt
histolog
evalu
demonstr
sever
nonsuppur
myocard
emerg
toxic
occur
due
absenc
circul
nara
mice
treat
highdos
cyclophosphamid
studi
system
reoviru
administr
mice
lack
matur
b
cell
fail
make
antivir
antibodi
confirm
similar
sever
toxic
occur
due
viral
replic
system
organ
rather
see
nogo
point
clinic
develop
immunosuppress
therapi
given
reoviru
decid
modifi
dose
schedul
cyclophosphamid
attempt
deriv
clinic
applic
regimen
accordingli
restructur
protocol
drug
given
day
intraven
reoviru
whole
socal
metronom
regimen
consist
repeat
therapi
separ
day
regimen
associ
high
level
intratumour
viral
deliveri
replic
pfumg
tumour
tumour
cure
importantli
nara
respons
preserv
albeit
attenu
level
system
toxic
mild
caus
death
anim
data
show
neutralis
antibodi
oncolyt
virus
capac
play
dual
role
one
hand
view
obstacl
hinder
repeat
inject
viru
hand
repres
safeguard
neutralis
viru
releas
vigor
intratumour
replic
thu
prevent
caus
viral
toxic
normal
tissu
direct
consequ
initi
phase
studi
intraven
reoviru
subsequ
preclin
studi
design
modul
immun
respons
viru
initi
phase
doseescal
studi
cyclophosphamid
combin
recommend
phase
ii
dose
reoviru
fig
studi
uniqu
endpoint
base
evid
modul
nara
respons
recruit
proceed
harrington
kj
person
commun
data
phase
studi
reoviru
administ
intratumour
intraven
rout
result
previou
studi
oncolyt
virus
singleag
therapi
convincingli
demonstr
like
signific
impact
standalon
therapi
howev
sound
mechanist
reason
believ
oncolyt
virus
combin
standard
anticanc
agent
clinic
benefit
much
way
monoclon
antibodi
small
molecul
inhibitor
review
consid
potenti
partner
therapi
use
alongsid
oncolyt
reoviru
abl
conceiv
number
potenti
posit
theoret
interact
ionis
radiat
first
radiat
may
increas
abil
reoviru
infect
tumour
cell
affect
express
cell
surfac
receptor
similar
effect
observ
adenoviru
infect
therapeut
irradi
second
cell
mutat
ra
rel
radioresist
sensit
reovirusinduc
oncolysi
third
stress
respons
irradi
cell
involv
increas
signal
egfrra
pathway
enhanc
reovir
replicationcytotox
fourth
radiationinduc
alter
proport
tumour
cell
differ
phase
cell
cycl
may
render
permiss
reoviru
infect
andor
replic
fifth
vivo
set
radiat
may
reduc
high
tumour
interstiti
pressur
signific
barrier
effect
intratumour
spread
biolog
particl
virus
therefor
complet
vitro
vivo
preclin
studi
evalu
combin
reoviru
radiat
rang
tumour
cell
line
initi
demonstr
reoviru
significantli
inactiv
even
larg
singl
fraction
xray
irradi
gy
minor
reoviru
cytotox
higher
radiat
dose
gy
radiat
dose
clinic
relev
thereaft
show
enhanc
cytotox
radiat
combin
reoviru
across
broad
rang
multipl
infect
moi
panel
tumour
cell
line
effect
combin
treatment
mark
low
moi
cell
line
show
modest
suscept
reoviru
cytotox
absenc
radiat
proceed
examin
natur
cooper
interact
radiat
reoviru
use
combin
index
methodolog
chou
talalay
strong
synerg
demonstr
tumour
cell
expos
gy
radiat
reoviru
moi
contrari
initi
hypothesi
radiat
may
alter
signal
environ
within
cell
make
conduc
reovir
replic
evid
enhanc
replic
reoviru
irradi
cell
line
cellular
mechan
underli
observ
increas
cytotox
combin
therapi
increas
apoptosi
final
combin
therapi
test
three
separ
anim
model
includ
immunodefici
immunocompet
system
three
model
evid
intratumour
inject
reoviru
abl
significantli
enhanc
therapeut
efficaci
fraction
cours
radiat
studi
form
basi
conduct
doseescal
phase
studi
determin
safeti
feasibl
combin
intratumour
reoviru
palli
radiotherapi
patient
advanc
cancer
secondari
goal
includ
assess
viral
biodistribut
excret
blood
urin
stool
sputum
reovir
replic
tumour
antivir
immun
respons
elig
patient
includ
measur
diseas
amen
palli
radiotherapi
order
maximis
inform
would
avail
studi
chose
adopt
novel
twostag
design
fig
first
stage
patient
receiv
radiotherapi
dose
gy
fraction
plu
two
intratumour
inject
reoviru
dose
tcid
second
stage
radiotherapi
dose
increas
gy
fraction
patient
receiv
two
four
six
dose
reoviru
stabl
dose
tcid
recruit
patient
varieti
solid
tumour
reassuringli
doselimit
toxic
seen
cohort
combin
treatment
associ
exacerb
acut
radiat
reaction
phase
studi
intraven
reoviru
conduct
rigor
programm
check
shed
viru
inject
patient
revers
transcript
polymeras
chain
reaction
rtpcr
studi
blood
urin
stool
sputum
neg
case
patient
treat
gy
radiat
group
evalu
patient
partial
respons
pr
stabl
diseas
sd
group
patient
treat
gy
fraction
evalu
patient
pr
sd
studi
shown
combin
intratumour
reoviru
radiotherapi
well
toler
show
favour
toxic
profil
absenc
vector
shed
inject
patient
mean
approach
easili
appli
outpati
set
howev
patient
popul
studi
preclud
formal
analysi
potenti
efficaci
approach
evalu
patient
newli
diagnos
cancer
receiv
radiotherapi
cur
intent
number
combin
chemotherapi
oncolyt
virus
alreadi
evalu
preclin
mani
studi
confirm
mark
antitumour
effect
without
signific
addit
toxic
review
rel
earli
develop
shown
enhanc
clinic
efficaci
combin
system
cisplatin
compar
chemotherapi
alon
patient
head
neck
cancer
therefor
prelud
conduct
clinic
studi
evalu
combin
reoviru
cytotox
chemotherapi
number
cell
line
includ
melanoma
prostat
cancer
head
neck
cancer
initi
studi
demonstr
synergist
activ
combin
chemotherapi
reoviru
malign
melanoma
cell
line
addit
cisplatin
significantli
enhanc
tumour
kill
compar
reoviru
alon
across
rang
moi
subsequ
isobolograph
analys
confirm
interact
synergist
particularli
cisplatin
paclitaxel
mechan
enhanc
cell
kill
increas
apoptosi
vivo
studi
confirm
greater
level
viral
replic
tumour
recov
anim
receiv
combin
therapi
also
complet
similar
studi
prostat
head
neck
cancer
cell
line
former
taxan
shown
synergist
reoviru
pandha
hs
person
commun
latter
platin
taxan
shown
exert
synergist
effect
harrington
kj
person
commun
base
data
phase
studi
intraven
reoviru
vitro
data
synergist
interact
reoviru
cisplatin
paclitaxel
design
phase
studi
three
agent
combin
patient
local
advanc
diseas
view
concern
potenti
viral
toxic
patient
receiv
fulldos
cytotox
chemotherapi
viru
administ
accord
doseescal
scheme
howev
start
dose
reduc
one
log
recommend
singleag
phase
ii
dose
thu
initi
phase
studi
cohort
patient
receiv
escal
dose
tcid
reoviru
day
combin
carboplatin
area
curv
paclitaxel
mgm
h
administ
day
schedul
patient
varieti
advanc
cancer
amen
cur
treatment
refractori
standard
therapi
treat
complet
doseescal
phase
compon
studi
phase
ii
studi
patient
head
neck
cancer
perform
doseescal
portion
studi
doselimit
toxic
patient
head
neck
cancer
receiv
least
two
cycl
treatment
thu
evalu
respons
pr
seen
patient
sd
pd
patient
head
neck
cancer
refractori
previou
platinumbas
chemotherapi
confirmatori
usbas
studi
patient
group
current
recruit
patient
find
prompt
success
submiss
feder
drug
administr
special
protocol
agreement
test
combin
carboplatin
paclitaxel
reoviru
versu
carboplatin
paclitaxel
placebo
randomis
phase
iii
trial
patient
platinumrefractori
relapsedmetastat
head
neck
cancer
fig
review
summaris
current
progress
clinic
develop
oncolyt
reoviru
reoviru
use
purpos
illustr
present
repres
agent
progress
furthest
along
track
clinic
assess
progress
back
extens
preclin
clinic
packag
agent
assess
standalon
therapeut
combin
regimen
radiotherapi
chemotherapi
stage
progress
facilit
acceler
pursu
modular
iter
approach
lesson
learn
laboratori
appli
clinic
vice
versa
believ
model
use
oncolyt
viral
therapi
move
forward
clinic
beyond
phase
set
schemat
view
infect
cycl
reoviru
initi
infect
occur
interact
virion
junction
adhes
molecul
sialic
acid
residu
cell
membran
viru
internalis
endosom
compart
partial
digest
form
intermedi
subvir
particl
isvp
viral
doublestrand
rna
dsrna
escap
endosom
cell
contain
normal
wildtyp
ra
gene
presenc
dsrna
lead
phosphoryl
pkr
subsequ
activ
turn
lead
shutdown
viral
protein
synthesi
thu
abort
product
infect
contrast
cell
mutant
ra
activ
ra
pathway
pkr
remain
hypophosphoryl
form
viral
rna
speci
abl
direct
synthesi
assembl
daughter
virion
modular
iter
natur
preclin
clinic
develop
oncolyt
virotherapi
black
arrow
chart
cours
preclin
clinic
trial
involv
use
singleag
reoviru
specif
data
emerg
initi
phase
studi
intraven
viral
administr
provid
essenti
data
immun
effect
patient
result
use
design
studi
laboratori
ultim
provid
mechan
attempt
modul
nara
respons
cyclophosphamid
blue
arrow
show
cours
studi
reoviru
combin
radiotherapi
immun
profil
key
compon
work
pink
arrow
indic
work
stream
combin
cytotox
chemotherapi
regard
phase
ii
combin
studi
complet
result
success
submiss
propos
phase
iii
trial
interpret
refer
color
figur
legend
reader
refer
web
version
articl
scheme
deliveri
cyclophosphamid
reoviru
reolysin
phase
studi
immunomodulatori
therapi
cyclophosphamid
deliv
day
cycl
reoviru
cycl
repeat
week
dose
level
written
protocol
case
doselimit
toxic
encount
cohort
need
studi
conduct
trial
design
phase
studi
reoviru
combin
radiotherapi
phase
ia
patient
cohort
receiv
palli
radiotherapi
dose
gy
fraction
x
gy
per
fraction
escal
dose
viru
v
deliv
day
cohort
viru
dose
cohort
viru
dose
cohort
dose
per
inject
phase
ib
patient
receiv
palli
radiotherapi
dose
gy
fraction
x
gy
per
fraction
increas
number
viru
administr
viru
dose
v
dose
level
patient
cohort
receiv
inject
cohort
receiv
inject
cohort
receiv
inject
clinic
trial
design
randomis
phase
iii
trial
carboplatin
paclitaxel
reoviru
placebo
patient
relapsedmetastat
platinrefractori
head
neck
cancer
scchn
squamou
cell
cancer
head
neck
auc
area
curv
cr
complet
respons
pr
partial
respons
sd
stabl
diseas
